Notícias Enlivex Therapeutics Ltd - ENLV | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Enlivex Therapeutics Ltd (ENLV)
Enlivex Therapeutics Ltd (ENLV) Notícias

Enlivex Therapeutics Ltd (ENLV)

1,08

0,00

(0,00%)

Fechado 05 Fevereiro 6:00PM

Atrasado por 15 minutos

1,085

0,005

(0,46%)

Após o horário de negociação: 9:59PM

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events

Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

1
2
3
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Enlivex Therapeutics

Exchange Traded Fund Ene...

iShares North American T...

High Mountain Capital

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições